Albuterol use in viral respiratory infections
Pro Research Analysisby 
Searched over 200M research papers
Albuterol Use in Viral Respiratory Infections: Frequency and Clinical Practice Patterns
Albuterol is commonly used in the management of viral respiratory infections, especially in children hospitalized with conditions like bronchiolitis. Despite clinical guidelines often advising against its routine use, studies show high rates of albuterol administration in practice. For example, in children hospitalized with human metapneumovirus (HMPV) infection, 69% received at least one albuterol treatment, even though only 31% had a documented history of wheezing. Importantly, there was no difference in hospital length of stay between those who received albuterol and those who did not, suggesting limited benefit in this context . Similarly, a large cross-sectional study found that 76.3% of infants hospitalized for viral bronchiolitis were prescribed albuterol, with age and longer hospital stays being predictors for its use. However, albuterol was less likely to be prescribed after the implementation of clinical practice guidelines and in infants with confirmed RSV infection .
Efficacy of Albuterol in Viral Bronchiolitis and RSV Infections
Multiple randomized controlled trials and observational studies have evaluated the effectiveness of albuterol in infants with viral bronchiolitis, including those with RSV. The evidence consistently shows that albuterol does not significantly improve primary outcomes such as time to illness resolution, respiratory rate, symptom scores, or oxygen saturation compared to placebo 247. For instance, a double-blind trial found no significant differences in symptom resolution or secondary outcomes between infants treated with oral albuterol and those given placebo . Another study comparing oral and nebulized albuterol to placebo in infants with bronchiolitis found no significant improvements in respiratory parameters or hospital admission rates . Objective measures of respiratory function, such as tidal breathing assessed by plethysmography, also did not show significant changes after albuterol administration .
Subgroups That May Benefit from Albuterol
While routine use of albuterol is not supported for all infants with viral bronchiolitis, some evidence suggests that specific subgroups may benefit from a therapeutic trial. Older infants with rhinovirus (RV) bronchiolitis, those with a history of wheezing, atopic dermatitis, or a family history of asthma, and those infected during non-RSV predominant months may have a greater likelihood of responding to albuterol . This targeted approach could help identify patients who might benefit from bronchodilator therapy, though further research is needed to confirm these findings .
Albuterol in Severe Cases and Mechanistic Insights
In severe RSV infections requiring mechanical ventilation, inhaled albuterol showed limited bronchodilator effect, with only a minority of infants experiencing small improvements in lung function. In some cases, lung function even deteriorated after albuterol administration, indicating that its use should be discontinued if no benefit is observed . Experimental studies in animal models suggest that the (R)-enantiomer of albuterol may have stronger anti-inflammatory effects than the racemic mixture, but these findings have not yet translated into clear clinical recommendations for routine use in children .
Safety and Delivery Considerations During Viral Outbreaks
Albuterol is generally considered safe, with only minor side effects such as increased heart rate reported in some studies 49. During the COVID-19 pandemic, alternative delivery protocols, such as common canister metered dose inhalers, were implemented to conserve supplies and reduce the risk of viral aerosolization, with most patients showing improved respiratory status .
Conclusion
Albuterol is frequently used in children with viral respiratory infections, especially bronchiolitis, despite limited evidence supporting its routine use. Most studies show no significant benefit in primary clinical outcomes, and guidelines recommend against widespread use. However, a therapeutic trial may be considered in select subgroups, such as older infants with certain risk factors. Ongoing research is needed to better define which patients, if any, are most likely to benefit from albuterol therapy in the context of viral respiratory infections.
Sources and full results
Most relevant research papers on this topic